Medicare AdvantageCoverageMedium impact
MA07.040c, Transcatheter Arterial Chemoembolization (TACE) of Hepatic Malignancies
Independence Blue Cross·Oncology, Radiology, Radiation Oncology·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Policy MA07.040c regarding Transcatheter Arterial Chemoembolization (TACE) for hepatic malignancies has been reissued effective March 5, 2025. This is a recent policy update that may contain changes to coverage criteria, prior authorization requirements, or billing guidelines for TACE procedures. The billing team must review the full policy details to identify specific changes from the previous version.
Action Required
By March 5, 2025: Billing team must obtain and review the complete policy text for MA07.040c at the provided URL to identify specific billing code changes, prior authorization requirements, or coverage modifications. Update billing software, encounter forms, and clinical staff alerts accordingly. Ensure all claims for TACE procedures on or after March 5, 2025 comply with reissued policy requirements. Failure to implement changes may result in claim denials or improper reimbursement.